HK-660S is under clinical development by Curome Bioscience and currently in Phase II for MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes). According to GlobalData, Phase II drugs for MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HK-660S LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HK-660S overview
HK-660S (Beta Lapachone) is under development for the treatment of primary sclerosing cholangitis and MELAS Syndrome. It is administered through oral route and acts by targeting NQO1.
It was under development for the treatment of age related macular degeneration, metabolic syndrome, obesity diabetes, hyperlipidemia, atherosclerosis, cardiovascular disease, chronic myelogenous leukemia and erectile dysfunction, and non alcoholic fatty liver disease.
Curome Bioscience overview
Curome Bioscience is a biotechnology company that develops therapies for intractable and rare diseases. The company’s product pipeline includes HK-660S drug candidate to treat primary sclerosing cholangitis; HK-1 for primary mitochondrial diseases; and CR-1 for treating inflammatory diseases. It is also developing other drug candidates such as CR-2 and CR-3, at the discovery stage for treatment of rare and degenerative diseases. Curome Bioscience works in partnerships with QuBEST Bio, C&R Research, Wuxi Apptec, and the Korea Institute of Science and Technology, among others. The company operates a research and development facility in Suwon, South Korea. Curome Bioscience is headquartered in Cheongju, South Korea.
For a complete picture of HK-660S’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
